Omvoh's approval as a treatment for Crohn's disease was based on results from a study in which 53% of patients treated with the drug achieved clinical remission, and 46% of patients had visible ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

BFA Law Announces that a Class Action has been filed against BioAge Labs, Inc. - Contact the Firm if You Suffered Losses ...

On Tuesday we’ll hop on BART to go down to the Hyatt Regency San Francisco for a portion of Fierce JPM Week. Our coverage ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

BioAge stated that it was collaborating with Eli Lilly and Company ("Lilly") in connection with STRIDES ... as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA ...

A new study from the University of Iowa finds that many drug prices actually drop after pharmaceutical company mergers, ...

NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ:BIOA) and certain of its ...